HB8270, the “Every Dollar Counts Act of 2026,” would require certain out-of-pocket spending on prescription drugs to be credited toward a person’s deductible and annual out-of-pocket maximum when the drug is covered by the plan but the enrollee chooses to buy it without using the plan’s pharmacy benefits. The bill applies this rule to group health plans and health insurance issuers under the Public Health Service Act, ERISA-covered employer plans, and the tax code provisions governing group health plans.
The measure also makes conforming changes to Medicaid drug pricing rules so that manufacturer price calculations exclude discounts tied to a person purchasing a drug outside of plan or federal program benefits. The effective date is generally for plan years beginning on or after January 1, 2027.
Impact
If enacted, the bill would change federal health coverage rules by forcing insurers and employer-sponsored plans to count certain direct drug purchases toward deductibles and out-of-pocket caps, potentially helping consumers who pay cash or use alternative pricing arrangements for covered medications. It would amend the Public Health Service Act, ERISA, and the Internal Revenue Code, and it would also adjust related Medicaid rebate and average manufacturer price definitions to exclude discounts associated with off-benefit purchases.
Sentiment
The available record shows no committee transcript or vote history, so there is no documented debate or recorded opposition in the provided materials. Based on the bill text alone, the measure appears consumer-protective and aimed at reducing prescription drug cost burdens for insured individuals who pay out of pocket.
Contention
The main policy issue is how the bill would interact with insurer benefit design and drug pricing practices. Supporters would likely emphasize lower patient costs and faster progress toward deductibles, while potential critics could focus on administrative complexity, cost-shifting to premiums, and the effect of excluding certain discounts from manufacturer pricing calculations. No specific member objections or amendments are available in the provided context.